Cancer is likely to affect up to one in three people in the developed world over their lifetimes but, in spite of impressive advances in understanding the molecular basis of cancer over recent years, leukaemia researcher Mel Greaves believes there is still widespread public misunderstanding about the disease. He has set out to counter that in a popular book* about the disease and believes a Darwinian, evolutionary approach is the best way to help a confused public and the patient who wonders 'Why me?'.
An evolutionary approach to aspects of the human condition has become fashionable in recent years. Randolph Nesse and George Williams coined the term 'Darwinian medicine' as a way of looking at how we get sick, and the approach of studying how our evolutionary past may throw light on current issues has been taken up enthusiastically in many fields.
We now know from advances in molecular genetics of the past 25 years that cancer develops as a chromosomal gene disorder in single cells. But it is different and more complex than the 5,000 or so other human genetic diseases that arise as inherited, single-gene traits. It is also different from the disease pattern the public most readily grasps of common infectious illnesses, caused by individual culprit microorganisms that are, on the whole, amenable to treatment or prevention. The simple formula, infection with X = disease Y: treat with Z is not applicable to cancer and is part of the cause for confusion and distress.
To begin to tackle this confusion, Greaves, head of the Leukaemia Research Fund Centre for Cell and Molecular Biology at the Institute of Cancer Research in London, starts with some history. Cancer is old. The prize for oldest identified tumour currently rests with a haemangioma (a benign tumour of blood vessels) and an uncertain cancer type whose unique imprints were identified in dinosaur bones from the Jurassic period, more than 150 million years ago. But more importantly, cancer appears intimately tied up with the development of multicellular organisms. "It reflects such an intrinsic feature of multicellular creatures that we can be reasonably confident that benign and malignant growths have been around for half a billion years or so," says Greaves.
"Understanding the causal mechanisms involved and the real why and how it happens is only possible with some biological archaeology -digging out what makes us tick, the deep legacies inherent in our design, and the pitfalls that can open the door to cancer." Again in contrast to the popular conception of infectious diseases, Greaves argues that in a sense every patient's cancer is unique. "In so far as it is a disease, it is a collection of very many (a thousand or so) disorders of cell and Evolutionary rift: An immunofluorescence light micrograph of prostate cancer cells. This is one of the common cancers that may result from a rift between our ancient evolutionary legacy and current lifestyles. (Nancy Kedersha, Science Photo Library.)
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Evolutionary lessons for cancer biology
A new popular book aims to use an evolutionary approach to help the public understand a common disease that does not behave like many others. Nigel Williams reports.
tissue function that have one special biological property in common -the territorial expansion of a mutant clone." The evolutionary approach, however, may not only illuminate how cancer might have emerged as a fundamental consequence of multicellular organisms but also throw light on how a single mutant cell might develop a clone that results in cancer.
At the heart of Greaves' account is how the evolutionary view flags up the conflict between modern human behaviour and our genetic inheritance.
"Homo sapiens occupy a special and unenviable place in the scheme of things. Superimposed on our very ancient genetic memories is a more recent, million-year-old evolutionary legacy that we acquired or modified as an emerging species of hominid primates," says Greaves. But it is a flawed inheritance as far as cancer is concerned. "Flawed by a double whammy from what were, originally, very advantageous adaptations. First, our ability to survive long after our natural reproductive period. Second, our propensity to interfere both with our own and other people's biology. Examples include our persistent pursuit of pleasure in the form of smoking, sunshine and sex and, rather less transparently, our adoption of diets, physical inactivity, and reproductive patterns that are at odds with our inherent biology" he says. The undesirable biological consequences are slow, chronic and stealth-like, impacting mostly after our normal reproductive period. They escape the filter of natural selection and conspire together to both outflank and exploit the efficacy of otherwise very resilient biological controls.
"We have become social beasts out of synch with our genetics, caught in a nature-nurture mismatch, our pedestrian genetics too slow to catch up with or adapt to our strident and exotic social habits. The consequence is accumulative damage and a potent ratcheting-up of risk for the emergence of cancer in an ageing and puzzled body," he says.
The molecular evidence of a progression of cells towards a cancerous state suggests that certain cell types may be more vulnerable. Cells with extensive longevity, replicative potential and migratory capacity should be most at risk of cancerous transformation. The cells concerned exist transiently in the developing embryo and foetus and, throughout life, in those tissues that are continually self-renewing, that proliferate on demand, or that can regenerate after injury (blood, skin, the linings of the lung, intestines, the endocrine glands, and liver). This prediction is amply fulfilled by the evidence of cancer types we have.
Superimposed on our very ancient genetic memories is a more recent milllion-year-old evolutionary legacy
It may be that we are under constant threat from potentially cancerous cells. "Most ageing men (say, 70 years plus) have a locally invasive carcinoma in the prostate gland as revealed by autopsy studies on prostate glands in individuals who died of non-malignant causes," says Greaves. "Similarly for breast cancer. The lifetime risk of carcinoma in situ (CIS) -a halfway house in cancer development -in the breast may be as high as one in four. In one so far unconfirmed Danish study of biopsies from medico-legal autopsies, one third of all women in their 40s had CIS. None were found in a small sample of women in their 20s."
The evolutionary perspective on cancer is initially depressing for patients. For a clone to succeed in establishing cancer suggests that it is robust and that any treatment is likely to leave a few cells unscathed which is all that is needed for the cancer to progress. Clearly, the odds are really stacked up against therapeutic success as the cancer clone evolves and expands. "It really is no surprise at all then, now we see more clearly the genetic and evolutionary game plan of cancer cells, that chemotherapy for metastatic disease most often fails as some mutant cells, insulated from the insult, escape through the most stringent of bottlenecks," says Greaves.
The reality, he says, is that treatment for cancer can be nasty and toxic, and doctors and scientists have overall done a rather poor job in explaining why this is so and what the underlying problems are. "And yet, there have been real improvements in clinical management, a revolution in our understanding of the underlying biology of cancer, and a much more sophisticated appreciation of the multiple factors involved in causation. At last we have some understanding what it really is, why the complexity exists."
And there is optimism arising from this evolutionary perspective. It flags up the potential to improve prevention of the disease and although it is unlikely that there will be any single, blanket treatments against cancer, there are aspects tumours have in common, such as developing a blood supply, that may provide a route in to tackling a range of tumours. "There still will not be a 'magic bullet', however sophisticated, for cancer in general," he argues. "Political leaders and advisers should now recognize that the problem isn't equivalent to the task of building the first atom bomb and getting man on the moon. The intricacies of millions of years of evolutionary biology are involved, richly embroidered and coupled in conflict with human diversity and behaviour."
*Cancer: The Evolutionary Legacy by Mel Greaves. Oxford University Press, Oxford OX2 6DP, UK.
